Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

MERIT-2 : Long Term, Multicenter, Single-arm, Open-label Extension Study of the MERIT-1 Study, to Assess the Safety, Tolerabilty and Efficacy of Macitentan in Subjects With Inoperable Chronic Thromboembolic Pulmonary Hypertension (CTEPH)

NCT02060721 is registered in ClinicalTrials.gov with Actelion as lead sponsor.

NCT NCT02060721
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02060721 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
MERIT-2 : Long Term, Multicenter, Single-arm, Open-label Extension Study of the MERIT-1 Study, to Assess the Safety, Tolerabilty and Efficacy of Macitentan in Subjects With Inoperable Chronic Thromboembolic Pulmonary Hypertension (CTEPH)
Lead sponsor
Actelion
Phase
Phase 2
Overall status
Completed
Start date
February 3, 2015
Completion date
March 21, 2022
Enrollment
76 (actual)
Sites
33

Conditions

As the registry lists them; a condition with its own page is linked.

chronic thromboembolic pulmonary hypertension